Professional Role and Affiliation
Dr. Efrat Dotan, MD is the Executive Medical Director of the Ann B. Barshinger Cancer Institute at Penn Medicine Lancaster General Health, a position she has held since October 2024. In addition to this primary leadership role, she serves as:
- Executive Medical Director, Cancer Services, Penn Medicine Lancaster General Health
- Executive Medical Director, Cancer Research, Penn Medicine Lancaster General Health
- Chairperson, Cancer Committee, Penn Medicine Lancaster General Health
She holds hospital privileges at Lancaster General Hospital, enabling her to provide direct patient care within the facility. Dr. Dotan is also part of the LG Health Physicians team focusing on Hematology and Medical Oncology.
Clinical Specialty and Patient Scope
Specializing in Hematology and Medical Oncology, Dr. Dotan treats patients aged 18 and older. Her clinical expertise primarily encompasses gastrointestinal malignancies, including pancreatic and biliary cancers, with a focus on developing treatment protocols for older adults who present unique clinical challenges.
Educational Background and Training
- Medical Degree: Technion - Israel Institute of Technology
- Residency: Lenox Hill Hospital
- Fellowship: Fox Chase Cancer Center
She has over 20 years of medical oncology experience, including a long tenure at Fox Chase Cancer Center from July 2007 to November 2024, where she served as Medical Oncologist and Chief of Gastrointestinal Medical Oncology. Prior to that, she completed chief medical residency at Lenox Hill Hospital (2006–2007).
Research and Academic Leadership
Dr. Dotan has an extensive research portfolio concentrated on geriatric oncology and clinical trials aimed at older adults with gastrointestinal cancers. She has been recognized for her work in:
- Leading national clinical trials investigating novel therapeutic avenues for pancreatic and gastrointestinal malignancies.
- Principal Investigator for national pancreatic cancer clinical trials under the National Cancer Institute’s Pancreas Task Force, for which she currently serves as Vice Chair.
- Developing and integrating baseline geriatric and quality of life (QOL) assessments into treatment paradigms.
- Exploring prognostic and predictive biomarkers associated with aging cancer populations to optimize therapy responses.
- Innovative contributions in palliative care educational programs for hematology-oncology fellowship training.
Her academic roles prior to joining Penn Medicine Lancaster General include Chief of the Division of Gastrointestinal Medical Oncology and Associate Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center and Temple Health.
Professional Recognitions and Patient Feedback
- Rated 5.0/5.0 based on 39 patient reviews on Penn Medicine’s provider platform.
- Featured in the prestigious Castle Connolly Top Doctors list.
- Noted for patient-centered communication, accessibility, empathy, and professional, efficient support teams.
- Leadership in expanding clinical trial availability at Ann B. Barshinger Cancer Institute aims to enhance cancer care options locally.
Insurance Networks and Accessibility
Dr. Dotan accepts a broad array of insurance providers, including but not limited to:
- Aetna
- Cigna Healthcare
- Highmark Blue Shield and Highmark Wholecare
- UnitedHealthcare and UnitedHealthcare Community Plan of PA
- Medicare and Medicaid (Pennsylvania)
- VA Insurance (Veterans CCN)
- Independence Blue Cross (IBC)
- Oscar Health Plan of PA
This extensive insurance acceptance facilitates wide patient access across diverse payer sources.
Geographic Location and Contact Information
Primary Location:
Ann B. Barshinger Cancer Institute
2102 Harrisburg Pike, Lancaster, PA 17601
Contact Number: 717-544-9400
Penn Medicine Main Line: 800-789-7366
Summary of Actionable Insights
Dr. Dotan is a highly experienced medical oncologist with significant leadership responsibility in cancer research, clinical services, and patient care at Penn Medicine Lancaster General Health. Her dual focus on clinical practice and clinical trial development—particularly in geriatric oncology and gastrointestinal cancers—positions her as a key decision-maker and influencer in oncology care innovations at this institution. Access to her extensive research and leadership network, especially related to pancreatic cancer and geriatric patient assessments, underscores opportunities for collaboration or engagement related to oncology therapeutics and clinical trial expansions.
Her role in managing and expanding cancer services at the Ann B. Barshinger Cancer Institute suggests she is actively focused on enhancing treatment offerings and patient experience. High patient satisfaction and comprehensive insurance acceptance support a strong patient-centered operational environment under her direction.
LinkedIn Profile: [https://www.linkedin.com/in/efrat-dotan-323a323](https://www.linkedin.com/in/efrat-dotan-323a323)
Penn Medicine Profile: [https://www.pennmedicine.org/providers/efrat-dotan](https://www.pennmedicine.org/providers/efrat-dotan)
